Sarepta Therapeutics (SRPT) Tops Q1 EPS by 217c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of $3.16, $2.17 better than the analyst estimate of $0.99. Revenue for the quarter came in at $730.8 million versus the consensus estimate of $474.26 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• Advance Auto Parts falls on revenue miss, weak guidance
• Deere shares climb as fiscal Q3 earnings and revenue top estimates